Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast CancerMelinda L. Telli, Andrea L. Richardson, Kirsten M. Timms et al.|Clinical Cancer Research|2016Cited by 1.2k
Integrating genomic features for non-invasive early lung cancer detectionJacob J. Chabon, Maximilian Diehn, Emily G. Hamilton et al.|Nature|2020Cited by 689
Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and <i>BRCA1</i>/<i>2</i> Mutation–Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105Melinda L. Telli, James M. Ford, Kirsten M. Timms et al.|Journal of Clinical Oncology|2015Cited by 226